Global Biologics Contract Development and Manufacturing Organizations Profiles Analysis Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Profiles and Growth Opportunities of Global Biologics Contract Development and Manufacturing Organizations” report has been added to from ResearchAndMarkets.com offer.

This report provides comprehensive insights into the Global Biologics Contract Development and Manufacturing Organizations (Bio-CDMO) Market, including emerging trends, growth opportunities and major bio-CDMO profiles and developments. of their business model.

The growth of next-generation biologics and personalized therapies and the emergence of small and medium-sized biotech companies are driving bio-CDMOs to become end-to-end integrated service providers for better customer value creation. Next-generation biologics require outsourcing in the early stages of development.

With limited or no in-house bioprocess development capacity for new modalities, large pharma and emerging small biotech companies are looking to outsource these services. To support the demand for outsourcing, bio-CDMOs are expanding to provide contract research services, leading them to adopt the CRDMO model: contract research, development and manufacturing.

The company profiles included in this research service offer a brief overview of the value proposition and strategic analysis of bio-CDMO. The report also highlights key strategic collaborations and expansion plans in the biopharmaceutical market.

Recent market expansion activities reflect the growing role of bio-CDMOs as a strategic partner in the development of new modalities. Bio-CDMOs enhance the ability and capacity to support modalities such as cell and gene therapy and mRNA.

The biopharmaceutical market is shifting towards these modalities following the success of mRNA technology in COVID-19 vaccines and therapeutics.

Research Highlights

  • Role of bio-CDMOs in scaling up the COVID-19 vaccine

  • Key Trends Shaping the Bio-CDMO Industry

  • In-house or outsourced biologics manufacturing capability

  • Key themes fostering collaborations/expansions

  • Recent notable acquisitions and capacity expansions by leading bio-CDMOs

Main topics covered:

1. Strategic imperatives

  • Why is it increasingly difficult to grow taller?

  • The strategic imperative

  • The impact of the top three strategic imperatives on the global biologics CDMO (Bio-CDMO) industry

  • Growth opportunities fuel the growth pipeline engine

2. Analysis of growth opportunities

  • Scope of analysis

  • Key Trends Shaping the Bio-CDMO Industry

  • Growth engines

  • Growth constraints

  • Role of bio-CDMOs in scaling up the COVID-19 vaccine

  • Key Manufacturing Partnerships with Bio-CDMOs for Approved COVID-19 Vaccines – United States

  • Key manufacturing partnerships with bio-CDMOs for approved COVID-19 vaccines – Europe

  • Trends in in-house manufacturing versus outsourcing

  • Key themes motivating Bio-CDMO collaborations/expansions

  • Recent Notable Acquisitions

  • Capacity Expansion Plans – Tier I Companies

  • Capacity Expansion Plans – Tier II/III Companies

  • Capacity expansion plans – specialized CDMOs and other businesses

  • Transition from CDMO to CRDMO

3. Company Profile-Lonza

  • Company Overview

  • Revenue and Technology Overview

  • Value proposition

  • Strategic analysis

3. Company Profile – Samsung Biologics

  • Company Overview

  • Revenue and Technology Overview

  • Value proposition

  • Strategic analysis

4. Company Profile – Boehringer Ingelheim BioXcellenceT

  • Company Overview

  • Revenue and Technology Overview

  • Value proposition

  • Strategic analysis

5. Company Profile – Thermo Fisher Scientific

  • Company Overview

  • Revenue and Technology Overview

  • Value proposition

  • Strategic analysis

6. Company Profile – WuXi Biologics

  • Company Overview

  • Revenue and Technology Overview

  • Value proposition

  • Strategic analysis

7. Company Profile – Catalent

  • Company Overview

  • Revenue and Technology Overview

  • Value proposition

  • Strategic analysis

8. Company Profile – AGC Biologics

  • Company Overview

  • Value proposition

  • Strategic analysis

9. Company Profile – WuXi AppTec

  • Company Overview

  • Revenue and Technology Overview

  • Value proposition

  • Strategic analysis

10. Universe of growth opportunities

  • Growth Opportunity 1 – Strategic partnerships to facilitate the transition from CDMO to CRDMO

  • Growth Opportunity 2 – Increase manufacturing capacity for pDNA

  • Growth Opportunity 3 – Small-scale agility to meet the specific CGT needs of emerging biopharmaceutical companies

For more information on this report, visit https://www.researchandmarkets.com/r/7gobme

Back To Top